In Brief: Heartport
This article was originally published in The Gray Sheet
Heartport: Acquires Utah Biomedical Test Laboratory, which the Redwood City, California company plans to use as the principal U.S. training center for its Port-Access minimally invasive cardiac surgery. Training is scheduled to begin this quarter at the 50,000-square-foot surgical laboratory. The facility will enable Heartport to "centralize and accelerate its U.S. training activities" and to "substantially accelerate and broaden its research and development activities," the firm says. On Oct. 7, Heartport received FDA clearance for the EndoCPB catheter system to perform Port-Access coronary artery bypass grafting and other cardiac surgeries. Heartport plans to launch the system by mid-1997 following physician training ("The Gray Sheet" Oct. 14, I&W-1)...
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.